Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043264
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2002-08-07
Brief Title:
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
Sponsor:
National Center for Research Resources NCRR
Organization:
National Center for Research Resources NCRR
Study Overview
Official Title:
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
Status:
COMPLETED
Status Verified Date:
2003-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple sclerosis MS is an inflammatory demyelinating disease which affects the central nervous system CNS The etiology of MS is unknown although the immune system appears to play a role Many different infectious agents have been proposed as potential causes for MS including Epstein-Barr virus human herpesvirus 6 and coronaviruses Recently Dr Sriram at Vanderbilt University has found evidence for active Chlamydia pneumonia infection in the CNS of MS patients These findings have been replicated in part by other laboratories
The purpose of the current study is to test whether antibiotic treatment aimed at eradicating Chlamydia infection will reduce the disease activity in MS The primary outcome measure will be reduction in new enhancing MS lesions on brain MRI Forty patients will be entered into the trial To be eligible patients must have evidence of chlamydia infection in their spinal fluid and enhancing lesions on their pre-randomization MRI scans Patients who meet these criteria will be randomized to either placebo or antibiotic therapy and followed for 6 months on treatment
The purpose of the current study is to test whether antibiotic treatment aimed at eradicating Chlamydia infection will reduce the disease activity in MS The primary outcome measure will be reduction in new enhancing MS lesions on brain MRI Forty patients will be entered into the trial To be eligible patients must have evidence of chlamydia infection in their spinal fluid and enhancing lesions on their pre-randomization MRI scans Patients who meet these criteria will be randomized to either placebo or antibiotic therapy and followed for 6 months on treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: